Exclusive license agreement includes rights to develop and commercialize Cedilla's CyclinE1/CDK2 inhibitors Assets are currently in pre-clinical development with potential to serve patients
Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors - read this article along with other careers information, tips and advice on BioSpace